Payers are more interested in effectiveness rather than efficacy of novel treatments. In light of health economics, cost-effectiveness is preferred over cost-efficacy. We aim to assess the use of real-world effectiveness evidence along with efficacy data reported in a clinical trial setting, to estimate effectiveness in a real-world setting with the example of overall survival (OS). For this purpose, we assess different (Bayesian) methodologies.